FDA Approves Combination of Immunotherapeutics for Melanoma
A new combination of cancer immunotherapeutics has been approved by the FDA for treating certain patients with melanoma.
Progress Against Cancer
A new combination of cancer immunotherapeutics has been approved by the FDA for treating certain patients with melanoma.
The former president, who announced in August 2015 he had metastatic melanoma, recently said he was cancer-free after treatment with pembrolizumab.
A small, early-phase trial of an investigational cancer immunotherapy yielded "durable responses" for patients with advanced melanoma and ocular melanoma.
The FDA recently approved new therapeutics for acute lymphoblastic leukemia, metastatic melanoma, and advanced ovarian cancer. In December 2014, the U.S. Food and Drug Administration (FDA) issued three approvals for new medications to treat...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now